TABLE 1.
Time point | HCV RNA level | Sensitivity (%)a | Specificity (%)b | PPV (%)c | NPV (%)d |
---|---|---|---|---|---|
Baseline | <400,000 IU/ml | 32 | 100 | 100 | 51 |
Day 21 | <10,000 IU/ml | 71 | 100 | 100 | 70 |
Day 21 | <100,000 IU/ml | 87 | 76 | 84 | 80 |
Wk 4 | <1,000 IU/ml | 68 | 95 | 95 | 68 |
Wk 4 | <15 IU/ml (negative) | 48 | 100 | 100 | 58 |
Wk 4 | <450,000 IU/ml | 97 | 36 | 68 | 89 |
Wk 12 | <50 IU/ml (negative) | 93 | 95 | 97 | 91 |
Wk 12 | <15 IU/ml (negative) | 90 | 95 | 97 | 88 |
Second slopee | >0.70 log IU/wk | 74 | 91 | 92 | 71 |
Second slopee | >0.35 log IU/wk | 97 | 73 | 83 | 94 |
Second slopef | >0.70 log IU/wk | 71 | 95 | 96 | 70 |
Second slopef | >0.35 log IU/wk | 100 | 73 | 84 | 100 |
Decrease, day 4 | >1.5 log IU | 45 | 100 | 100 | 53 |
Decrease, wk 12 | >2 log IU | 100 | 50 | 74 | 100 |
Sensitivity, proportion of patients with SVR who had HCV RNA levels below, a slope value above, or HCV RNA reduction above the given limit.
Specificity, proportion of patients with non-SVR who did not have HCV RNA below, a slope value above, or HCV RNA reduction above the given limit.
PPV, proportion of patients with HCV RNA below, a slope value above, or HCV RNA reduction above the given limit who achieved SVR.
NPV, proportion of patients without HCV RNA below, a slope value above, or HCV RNA reduction above the given limit who did not achieve SVR.
Based on HCV RNA levels at days 7, 14, and 21.
Based on all HCV RNA values.